Michael U J Oliphant
Overview
Explore the profile of Michael U J Oliphant including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
205
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kozlova N, Cruz K, Doh H, Ruzette A, Willis N, Hong S, et al.
bioRxiv
. 2025 Feb;
PMID: 39896456
Summary Paragraph: Drug resistance is a severe clinical problem in stroma-rich tumours, such as pancreatic ductal adenocarcinoma (PDAC), and patients often relapse within a few months on chemotherapy . The...
2.
Chang K, Silvestri F, Oliphant M, Martinez-Gakidis M, Orgill D, Garber J, et al.
NPJ Breast Cancer
. 2024 Dec;
10(1):107.
PMID: 39702422
Organoid cultures offer a powerful technology to investigate many different aspects of development, physiology, and pathology of diverse tissues. Unlike standard tissue culture of primary breast epithelial cells, breast organoids...
3.
Li C, Cordes A, Oliphant M, Quinn S, Thomas M, Selfors L, et al.
Nat Genet
. 2024 Nov;
56(12):2842.
PMID: 39567749
No abstract available.
4.
Williams M, Oliphant M, Au V, Liu C, Baril C, OFlanagan C, et al.
Nat Genet
. 2024 Nov;
56(12):2753-2762.
PMID: 39567747
The prevalence and nature of somatic copy number alterations (CNAs) in breast epithelium and their role in tumor initiation and evolution remain poorly understood. Using single-cell DNA sequencing (49,238 cells)...
5.
Li C, Cordes A, Oliphant M, Quinn S, Thomas M, Selfors L, et al.
Nat Genet
. 2024 Nov;
56(12):2763-2775.
PMID: 39528827
Germline BRCA1 mutation carriers face a high breast cancer risk; however, the underlying mechanisms for this risk are not completely understood. Using a new genetically engineered mouse model of germline...
6.
Taabazuing C, Henry W, Oliphant M, Lawrence S
Trends Pharmacol Sci
. 2024 Oct;
45(11):943-949.
PMID: 39477739
No abstract available.
7.
Oliphant M, Akshinthala D, Muthuswamy S
Breast Cancer Res
. 2024 Mar;
26(1):56.
PMID: 38553763
Patient-derived organoid models of estrogen receptor-positive (ER+) breast cancer would provide a much-needed tool to understand drug resistance and disease progression better. However, the establishment and long-term maintenance of ER...
8.
Wolin A, Vincent M, Hotz T, Purdy S, Rosenbaum S, Hughes C, et al.
Neuro Oncol
. 2023 Jul;
25(12):2287-2301.
PMID: 37486991
Background: Medulloblastoma is the most common pediatric brain malignancy. Patients with the Group 3 subtype of medulloblastoma (MB) often exhibit MYC amplification and/or overexpression and have the poorest prognosis. While...
9.
Paul I, Bolzan D, Youssef A, Gagnon K, Hook H, Karemore G, et al.
Nat Commun
. 2023 Feb;
14(1):688.
PMID: 36755019
A proper understanding of disease etiology will require longitudinal systems-scale reconstruction of the multitiered architecture of eukaryotic signaling. Here we combine state-of-the-art data acquisition platforms and bioinformatics tools to devise...
10.
Gil Del Alcazar C, Trinh A, Aleckovic M, Jimenez E, Harper N, Oliphant M, et al.
Cancer Immunol Res
. 2022 Apr;
10(6):680-697.
PMID: 35446942
Animal models are critical for the preclinical validation of cancer immunotherapies. Unfortunately, mouse breast cancer models do not faithfully reproduce the molecular subtypes and immune environment of the human disease....